Avenue Therapeutics to present preclinical in vivo data on BAER-101

Avenue Therapeutics will be presenting preclinical in vivo data evaluating BAER-101 using the SynapCell’s Genetic Absence Epilepsy Rat from Strasbourg model of absence epilepsy at the American Epilepsy Society 2023 Annual Meeting in Orlando, FL on December 2, 2023. BAER-101 underwent preclinical in vivo evaluation in SynapCell’s Genetic Absence Epilepsy Rat from Strasbourg model of absence epilepsy. The GAERS model, which is a proven, early, informative indicator of efficacy in anti-seizure drug development with high predictability of response in humans, mimics behavioral, electrophysiological and pharmacological features of human absence seizures. In the model, BAER-101 demonstrated full suppression of seizure activity with a minimal effective dose of 0.3 mg/kg, PO. The effect was fast in onset and stable throughout the duration of testing. The combination of safety and tolerability in hundreds of patients and the preclinical efficacy data support BAER-101’s continued development in a Phase 2a trial.